Home0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Nakaraang pagsara
$0.41
Sakop ng araw
$0.41 - $0.42
Sakop ng taon
$0.30 - $0.62
Market cap
3.94B HKD
Average na Volume
887.22K
P/E ratio
-
Dividend yield
-
Primary exchange
HKG
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (HKD) | Hun 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.32B | 2.20% |
Gastos sa pagpapatakbo | 323.51M | -4.23% |
Net na kita | 500.50K | -97.29% |
Net profit margin | 0.04 | -97.20% |
Kita sa bawat share | — | — |
EBITDA | 117.12M | 36.03% |
Aktuwal na % ng binabayarang buwis | 79.96% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (HKD) | Hun 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 562.09M | 11.10% |
Kabuuang asset | 10.89B | -1.45% |
Kabuuang sagutin | 6.87B | -0.11% |
Kabuuang equity | 4.01B | — |
Natitirang share | 9.61B | — |
Presyo para makapag-book | 0.98 | — |
Return on assets | 1.75% | — |
Return on capital | 1.91% | — |
Cash Flow
Net change in cash
| (HKD) | Hun 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 500.50K | -97.29% |
Cash mula sa mga operasyon | 72.70M | 80.63% |
Cash mula sa pag-invest | -47.88M | -484.81% |
Cash mula sa financing | -77.72M | 41.39% |
Net change in cash | -57.56M | 42.02% |
Malayang cash flow | 35.56M | 91.21% |
Tungkol
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
Itinatag
2000
Website
Mga Empleyado
1,968
